Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in Primary Sjogren's Disease
NCT06979531Phase 2Active, not recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Jun 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of IMVT-1402, sponsored by Immunovant, Inc.. Started Jun 2025; status: active, not recruiting.
02
Drugs
IMVT-1402
Beyond the preview
Go deeper on NCT06979531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979531.